NYSE · Health care

GLAUKOS Corp (GKOS)

GLAUKOS Corp brought in $690.3M of revenue over the twelve months to September 30, 2026, up 46.9% from a year earlier. It posted a net loss of $169.8M. In fiscal 2025 capital spending exceeded operating cash flow by $22.5M. At September 30, 2026 it held $162.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 28, 2026.

Watch GKOS in 60 seconds

Price

$238.74

+6.39% on the day · November 9, 2026

52-week range $83.78 to $255.19

Market cap

$14.1B

Revenue (last 12 months)

$690.3M

+46.9% year on year

Net margin

-24.6%

Key facts about GLAUKOS Corp

Net worth: GLAUKOS Corp has a market value (market cap) of $14.1B at the latest share price, and shareholders' equity of $717.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $507.4M (+32.3% year on year), with a net loss of $187.7M. Over the 12 months to September 30, 2026: revenue $690.3M, net loss $169.8M.
Cash flow: In fiscal 2025 operations used $14.8M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 28, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: GLAUKOS Corp's next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What GLAUKOS Corp does

GLAUKOS Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker GKOS.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$507.4M	-$199.6M	-$187.7M	-$3.28	-$22.5M
2024	$383.5M	-$122.4M	-$146.4M	-$2.77	-$67.6M
2023	$314.7M	-$128.7M	-$134.7M	-$2.78	-$78M
2022	$282.9M	-$82.3M	-$99.2M	-$2.09	-$63.3M
2021	$294M	-$32.9M	-$49.6M	-$1.07	-$23.1M
2020	$225M	-$123.6M	-$120.3M	-$2.70	-$29.9M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around January 12, 2027.

Estimated from its filing rhythm: 52 weeks after its report of January 13, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where GKOS ranks in Health care

Revenue$507.4M

#203 of 751 in Health care · Top 27%

Revenue growth+32.3%

#131 of 532 in Health care · Top 24%

Net margin-37.0%

#373 of 544 in Health care · Bottom 31%

Free cash flow margin-4.4%

#275 of 490 in Health care · Bottom 44%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What GLAUKOS Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 6, 2026
Investor disclosure 8-K
October 28, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue rose 58% to $211M versus the same quarter last year; diluted EPS $0.03 versus -$0.28.
October 28, 2026
Quarterly results 8-K
August 3, 2026
Investor disclosure 8-K
July 29, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 50% to $185.6M versus the same quarter last year; diluted EPS -$0.31 versus -$0.34.
July 29, 2026
Quarterly results 8-K
June 3, 2026
Shareholder vote results 8-K
May 29, 2026
Conflict minerals disclosure SD
May 15, 2026
Passive stake changed SCHEDULE 13G/A
May 4, 2026
Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 5, 2026. Insider transactions on SEC

Insider trades

What the people running GLAUKOS Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $15M worth of shares in the last 90 days and bought none on the open market. 5% of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$15M

last 90 days

Net sold

67,779

$15M

Date	Insider	What	Shares	Price	Value	Filing
November 4, 2026	Kliman Gilbert HDirector	Exercised options	2,500	$25.77	$64.4K	Form 4
November 4, 2026	Kliman Gilbert HDirector	Sold	2,500	$253.00	$632.5K	Form 4
October 30, 2026	Navratil TomasCHIEF DEVELOPMENT OFFICER	Exercised options	4,181	$55.00	$230K	Form 4
October 30, 2026	Navratil TomasCHIEF DEVELOPMENT OFFICER	Exercised options	8,788	$85.94	$755.2K	Form 4
October 30, 2026	Navratil TomasCHIEF DEVELOPMENT OFFICER	Sold	10,221	$237.54	$2.4M	Form 4
October 30, 2026	Navratil TomasCHIEF DEVELOPMENT OFFICER	Sold	12,836	$238.56	$3.1M	Form 4
October 30, 2026	Navratil TomasCHIEF DEVELOPMENT OFFICER	Sold	14,943	$239.64	$3.6M	Form 4
October 30, 2026	Navratil TomasCHIEF DEVELOPMENT OFFICER	Sold	6,436	$240.52	$1.5M	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GKOS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Janus Henderson Group PLC13G, passive	9.2%	5,348,395	May 15, 2026
Primecap Management Co13G, passive	5.88%	3,376,928	February 11, 2026
Vanguard Portfolio Management13G, passive	5.6%	3,256,962	April 29, 2026
Vanguard Capital Management13G, passive	5.07%	2,947,047	April 29, 2026

Latest filings below 5%: The Vanguard Group 0% (March 26, 2026); Wellington Management Group LLP 0.8% (February 10, 2026); Fmr LLC 4.5% (August 7, 2025); Thomas W. Burns 4.4% (February 12, 2025); Brown Capital Management, LLC 2.97% (November 14, 2024).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 366 managers reported a position.

Holder	Shares	Value	Change on quarter
BlackRock, Inc.	9,540,056	$1.33B	+450,027
Jupiter Topco LLC	4,862,894	$679.6M	new
Vanguard Portfolio Management LLC	3,321,839	$464.3M	+113,476
Primecap Management Co	3,040,705	$425M	-329,923
Vanguard Capital Management LLC	2,551,132	$356.5M	+42,361
State Street Corp	2,315,568	$323.7M	+132,951
Millennium Management LLC	1,581,016	$221M	+407,320
Holocene Advisors, LP	1,514,931	$211.7M	+131,216
Geode Capital Management, LLC	1,463,448	$204.6M	+106,995
Citadel Advisors LLC	1,390,017	$194.3M	-56,909
Ameriprise Financial Inc	1,315,057	$183.8M	-295,717
Capital World Investors	1,015,943	$142M	+26,883
Alliancebernstein L.P.	1,254,703	$135.1M	-142,853
Goldman Sachs Group Inc	897,021	$125.4M	-477,937
Charles Schwab Investment Management Inc	752,642	$105.2M	+38,253
Invesco Ltd.	706,877	$98.8M	-207,311
William Blair Investment Management, LLC	661,675	$92.5M	-412,144
Driehaus Capital Management LLC	650,571	$90.9M	+162,659
Nomura Asset Management International Inc.	647,428	$90.5M	+35,365
Northern Trust Corp	612,496	$85.6M	+36,287

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

11 insiders reported holding 1,643,923 shares in total, about $392.5M at the last price.

Holder	Shares	As of
Burns Thomas WilliamCHAIRMAN & CEO, Director	1,210,5601,141,593 held indirectly	June 25, 2026
Gilliam Joseph EPRESIDENT & COO	72,588	August 11, 2026
Foley Mark JDirector	60,267	May 28, 2026
Hoffmeister David FDirector	49,549	May 28, 2026
Weisner Aimee SDirector	47,68831,887 held indirectly	October 30, 2026
Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER	43,906	August 7, 2026
Stapley MarcDirector	39,327	May 28, 2026
Kliman Gilbert HDirector	37,406	November 4, 2026
Navratil TomasCHIEF DEVELOPMENT OFFICER	37,328	October 30, 2026
Torres DeniceDirector	24,212	May 28, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GKOS

What does GLAUKOS Corp do?

GLAUKOS Corp is a company in the Health care sector, listed on NYSE as GKOS. Its shares trade on NYSE under the ticker GKOS.

What is GLAUKOS Corp's net worth?

GLAUKOS Corp has a market value (market cap) of $14.1B at the latest share price, and shareholders' equity of $717.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is GLAUKOS Corp profitable?

No. Over the twelve months to September 30, 2026 it reported a net loss of $169.8M on revenue of $690.3M.

How much revenue does GLAUKOS Corp make?

Over the twelve months to September 30, 2026 GLAUKOS Corp reported revenue of $690.3M. That is 46.9% more than a year earlier.

When did GLAUKOS Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on October 28, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 6, 2026.

When is GLAUKOS Corp's next earnings report?

GLAUKOS Corp's next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

SOLV

Solventum Corp

BAX

Baxter International Inc

West Pharmaceutical Services Inc

Compare GKOS with

Compare GKOS with any company

Follow GKOS

Get an email when GLAUKOS Corp files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values GLAUKOS Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.